A phase 2b, open-label, two-cohort study of subcutaneous amivantamab in combination with lazertinib as first-line treatment, or subcutaneous amivantamab in combination with platinum-based chemotherapy as second-line treatment, for common EGFR-mutated locally advanced or metastatic non-small cell lung cancer

To join this study, you must be 18 years or older and have a diagnosis of advanced or widespread non-small cell lung cancer that cannot be cured by surgery. Your cancer must also have a specific genetic change in the EGFR gene (either Exon 19 deletion or Exon 21 L858R substitution).

You must be in reasonably good general health, and your cancer needs to have at least one area that can be measured by scans. If you have brain tumours that are not causing symptoms or have been treated and are stable, you might still be able to join. For people in the UK, this study is only for those who have not had any previous treatment for their advanced or widespread lung cancer.

If you join this study, your journey will have three main parts. First, there's a "Screening Phase" that can last up to 28 days. During this time, doctors will do checks to make sure the study is right for you. If you qualify and agree, you'll move to the "Treatment Phase".

During the treatment phase, if you live in the UK, you will receive a combination of amivantamab as an injection under your skin and lazertinib as a pill you take by mouth. This treatment continues until your cancer gets worse, or you're no longer able to take the medicine, or decide to stop. Throughout this period, you'll have regular hospital visits for treatments, health checks, and to see how well the drugs are working. After treatment ends, there's a "Follow-up Phase" where doctors will keep in touch to monitor your health either until the study finishes, your condition changes, or you choose to withdraw. The study is expected to run from August 2025 to November 2030, so regular monitoring will be over several years.